ENAMEX ID="NYU_ENAMEX2996" TYPE="ORGANIZATION" START="93" END="114" TEXT="evidence review group"
ENAMEX ID="NYU_ENAMEX2995" TYPE="ORGANIZATION" START="116" END="119" TEXT="ERG"
RELATION ID="NYU_RELATION2997" TYPE="ABBREVIATE" START="93" END="119" ARG1="NYU_ENAMEX2996" ARG1_NAME="FULLNAME" ARG2="NYU_ENAMEX2995" ARG2_NAME="SHORTNAME" ARG1_TEXT="evidence review group" ARG2_TEXT="ERG" GRAM_SIGNAL="PARENTHESES"
JARGON ID="NYU_JARGON2999" START="574" END="619" TEXT="pegylated liposomal doxorubicin hydrochloride"
JARGON ID="NYU_JARGON2998" START="621" END="625" TEXT="PLDH"
RELATION ID="NYU_RELATION3000" TYPE="ABBREVIATE" START="574" END="625" ARG1="NYU_JARGON2999" ARG1_NAME="FULLNAME" ARG2="NYU_JARGON2998" ARG2_NAME="SHORTNAME" ARG1_TEXT="pegylated liposomal doxorubicin hydrochloride" ARG2_TEXT="PLDH" GRAM_SIGNAL="PARENTHESES"
JARGON ID="NYU_JARGON3002" START="753" END="780" TEXT="randomised controlled trial"
JARGON ID="NYU_JARGON3001" START="782" END="785" TEXT="RCT"
RELATION ID="NYU_RELATION3003" TYPE="ABBREVIATE" START="753" END="785" ARG1="NYU_JARGON3002" ARG1_NAME="FULLNAME" ARG2="NYU_JARGON3001" ARG2_NAME="SHORTNAME" ARG1_TEXT="randomised controlled trial" ARG2_TEXT="RCT" GRAM_SIGNAL="PARENTHESES"
JARGON ID="NYU_JARGON3005" START="1314" END="1340" TEXT="quality-adjusted-life-year"
JARGON ID="NYU_JARGON3004" START="1342" END="1346" TEXT="QALY"
RELATION ID="NYU_RELATION3006" TYPE="ABBREVIATE" START="1314" END="1346" ARG1="NYU_JARGON3005" ARG1_NAME="FULLNAME" ARG2="NYU_JARGON3004" ARG2_NAME="SHORTNAME" ARG1_TEXT="quality-adjusted-life-year" ARG2_TEXT="QALY" GRAM_SIGNAL="PARENTHESES"
JARGON ID="NYU_JARGON3008" START="1358" END="1384" TEXT="mixed treatment comparison"
JARGON ID="NYU_JARGON3007" START="1386" END="1389" TEXT="MTC"
RELATION ID="NYU_RELATION3009" TYPE="ABBREVIATE" START="1358" END="1389" ARG1="NYU_JARGON3008" ARG1_NAME="FULLNAME" ARG2="NYU_JARGON3007" ARG2_NAME="SHORTNAME" ARG1_TEXT="mixed treatment comparison" ARG2_TEXT="MTC" GRAM_SIGNAL="PARENTHESES"
